Mayne Pharma Group Ltd has released a press release.
Appendix 4E and Statutory Accounts
Filed with ASX ·
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Mayne Pharma Group Ltd. on 6ix
In the deck
Earlier from Mayne Pharma
- Mayne Pharma Group: CEO announces plan to retire
- Mayne Pharma announces sale of Metrics Contract Services
- Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of Nuvaring
- Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS and expand access to birth control
- Mayne Pharma Group Limited and Mithra Pharmaceuticals - NEXTSTELLIS ORAL CONTRACEPTIVE NOW AVAILABLE IN AUSTRALIA
Later from Mayne Pharma
- 2022 Full Year Media Release
- 2022 Full Year Investor Presentation
- Mayne Pharma Group - non-executive Director appointment and retirement
- Mayne Pharma appoints new CEO
- Mayne Pharma - appointment of chief executive officer and Managing Director
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma